

Morbidity and Mortality Weekly Report

November 1, 2013

MMWR1311A

National Epilepsy Month -November 2013

November is National Epilepsy Awareness Month. Epilepsy is a brain disorder characterized by recurrent seizures; it affects approximately 2.3 million adults in the United States (1).

The CDC Prevention Research Centers' Managing Epilepsy Well (MEW) Network includes U.S. universities, the Epilepsy Foundation, and other epilepsy groups (2). The MEW Network works to develop and test programs that improve self-management and quality of life for persons with epilepsy.

Several MEW Network programs are available. WebEase is an Internet-based program (https://www.epilepsyfoundation.org/livingwithepilepsy/webease/index.cfm) shown to improve some epilepsy self-management outcomes (3). UPLIFT is an Internet and telephone-based program to treat depression in adults with epilepsy (4), with training for health-care providers available at http://www.sph.emory. edu/ManagingEpilepsyWell/UPLIFT. PEARLS is a collaborative-care depression treatment program for adults with epilepsy (5) with training for health-care providers available at http://www.pearlsprogram.org. Additional information regarding the MEW Network and related resources (such as webinars and podcasts) is available at http://www.cdc. gov/epilepsy and @mewnetwork on Twitter.

References

- 1. CDC. Epilepsy in adults and access to care—United States, 2010. MMWR 2012;61:909–13.
- 2. DiIorio C, Bamps Y, Edwards AL, et al. The Prevention Research Centers' Managing Epilepsy Well Network. Epilepsy Behav 2010;19:218-24.
- 3. Dilorio C, Bamps Y, Walker ER, Escoffery C. Results of a research study evaluating WebEase, an online epilepsy self-management program. Epilepsy Behav 2011;22:469-74.
- 4. Thompson NJ, Walker ER, Obolensky N, et al. Distance delivery of mindfulness-based cognitive therapy for depression: Project UPLIFT. Epilepsy Behav 2010;19:247–54.
- 5. Chaytor N, Ciechanowski P, Miller JW, et al. Long-term outcomes from the PEARLS randomized trial for the treatment of depression in patients with epilepsy. Epilepsy Behav 2011;20:545-9.

Comorbidity in Adults with Epilepsy - United States, 2010

Epilepsy, a spectrum disorder characterized by recurring seizures, affects approximately 2.3 million U.S. adults (1,2). Epilepsy poses challenges because of uncontrolled seizures, treatment complexity, social disadvantages (e.g., unemployment), and stigma (2,3). Persons with epilepsy are at increased risk for early mortality and for comorbidities that can complicate epilepsy management, increase health-care costs, and shorten the lifespan (2, 4-7). Numerous studies have described higher rates of psychiatric comorbidity (e.g., depression and anxiety) in persons with epilepsy (2,7).* However, fewer studies have examined nonpsychiatric comorbidity in a nationally representative U.S. sample of adults with epilepsy. To assess the prevalence of nonpsychiatric comorbidities, CDC analyzed data from the 2010 National Health Interview Survey (NHIS). Adults with epilepsy had a higher prevalence of cardiovascular,

INSIDE

- 854 Influenza Vaccination Among Pregnant Women - Massachusetts, 2009-2010
- 858 Global Routine Vaccination Coverage 2012
- 862 Notes from the Field: Outbreaks of Cyclosporiasis United States, June–August 2013
- 863 Notes from the Field: Salmonella Typhimurium Infections Associated with a Community College Microbiology Laboratory — Maine, 2013
- 864 Announcements
- 865 QuickStats

Continuing Education examination available at http://www.cdc.gov/mmwr/cme/conted_info.html#weekly.



U.S. Department of Health and Human Services Centers for Disease Control and Prevention

^{*} For example, the prevalence of any mental health disorder in the past 12 months was found to be 23.5% among persons with epilepsy, compared with 10.9% among those without epilepsy, and the lifetime prevalence of suicidal ideation was 25.0% in persons with epilepsy, compared with 13.3 % in those without epilepsy (7).

respiratory, some inflammatory, and other disorders (e.g., headache, migraine, and various other types of pain) than adults without epilepsy. Public health agencies can work with healthcare providers, the Epilepsy Foundation, and other partners to ensure that adults with epilepsy have access to health promotion resources and chronic disease self-management programs.

CDC analyzed data from adults aged ≥18 years who responded to NHIS, an annual cross-sectional survey of the civilian, non-institutionalized U.S. population.[†] The NHIS Sample Adult component included questions that determined epilepsy status. Adults who responded "yes" to ever having been told by a doctor or other health professional that they had a seizure disorder or epilepsy were considered as having "any epilepsy." Those with any epilepsy who either were currently taking medication to control it, had one or more seizures in the past year, or both were classified as having "active epilepsy" (1). Those with any epilepsy who were neither taking medication for epilepsy nor had a seizure in the past year were classified as having "inactive epilepsy" (1). All remaining adults were classified as having "no history of epilepsy." These case-ascertainment questions and case definitions meet standards for epidemiologic studies of epilepsy, including having acceptable positive predictive values for identifying clinical cases of epilepsy (1).

Nonpsychiatric conditions that were selected included some shown to be previously associated with epilepsy, and others not widely examined, but of interest to epilepsy providers (e.g., any liver condition). Statistical software was used to account for the complex NHIS survey design. Percentage estimates were ageadjusted to the 2000 U.S. Census population to account for age as a confounder and to facilitate comparisons.[¶] Estimates were considered reliable if their relative standard errors were <30% and differences were considered statistically significant if their 95% confidence intervals did not overlap. All reported differences are statistically significant. The 2010 NHIS Sample Adult Component conditional response rate was 77.3%, and the final response rate was 60.8%.

Cardiovascular and metabolic disorders and their associated risk factors were common among adults with epilepsy (Table). The age-adjusted prevalence of any heart disease was higher among adults with any epilepsy (18.3%), including both active epilepsy (19.5%) and inactive epilepsy (16.7%), than among those without epilepsy (11.3%). Adults with any epilepsy were more likely to have been told they had high blood pressure (34.2%) than those without epilepsy (29.0%). More adults across all epilepsy groups (range: 8.8%–18.3%) had experienced a stroke than adults without epilepsy (2.4%). More adults with any epilepsy (7.1%) were told they had prediabetes

The MMWR series of publications is published by the Center for Surveillance, Epidemiology, and Laboratory Services, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, GA 30333.

Suggested citation: Centers for Disease Control and Prevention. [Article title]. MMWR 2013;62:[inclusive page numbers].

Centers for Disease Control and Prevention

Thomas R. Frieden, MD, MPH, Director Harold W. Jaffe, MD, MA, Associate Director for Science Joanne Cono, MD, ScM, Acting Director, Office of Science Quality Chesley L. Richards, MD, MPH, Deputy Director for Public Health Scientific Services

MMWR Editorial and Production Staff

Ronald L. Moolenaar, MD, MPH, Editor, MMWR Series

John S. Moran, MD, MPH, Deputy Editor, MMWR Series Teresa F. Rutledge, Managing Editor, MMWR Series Douglas W. Weatherwax, Lead Technical Writer-Editor Donald G. Meadows, MA, Jude C. Rutledge, Writer-Editors Martha F. Boyd, Lead Visual Information Specialist Maureen A. Leahy, Julia C. Martinroe, Stephen R. Spriggs, Terraye M. Starr *Visual Information Specialists* Quang M. Doan, MBA, Phyllis H. King *Information Technology Specialists*

MMWR Editorial Board

William L. Roper, MD, MPH, Chapel Hill, NC, Chairman

Matthew L. Boulton, MD, MPH, Ann Arbor, MI Virginia A. Caine, MD, Indianapolis, IN Barbara A. Ellis, PhD, MS, Atlanta, GA Jonathan E. Fielding, MD, MPH, MBA, Los Angeles, CA David W. Fleming, MD, Seattle, WA William E. Halperin, MD, DrPH, MPH, Newark, NJ King K. Holmes, MD, PhD, Seattle, WA Timothy F. Jones, MD, Nashville, TN Rima F. Khabbaz, MD, Atlanta, GA Dennis G. Maki, MD, Madison, WI Patricia Quinlisk, MD, MPH, Des Moines, IA Patrick L. Remington, MD, MPH, Madison, WI William Schaffner, MD, Nashville, TN

[†]Additional information available at http://www.cdc.gov/nchs/nhis.htm.

[§] Five cases of epilepsy lacked information on medication usage or on seizure occurrence and could not be classified as either active or inactive.

SAge groupings used for age-adjustment were 18–44, 45–64, 65–74, and ≥75 years. Age-adjustment standards are available at http://seer.cancer.gov/stdpopulations/stdpop.singleages.html.

| | No history of epilepsy | | | Any epilepsy | | | | Active epilepsy | | | Inactive epilepsy | | |
|--------------------------------|------------------------|------|-------------|--------------|------|-------------|-----|-----------------|-------------|-----|-------------------|-------------|--|
| Condition | No. | % | (95% CI) | No. | % | (95% CI) | No. | % | (95% CI) | No. | % | (95% CI) | |
| Total [§] | 26,659 | 98.2 | (98.0–98.5) | 480 | 1.8 | (1.5–2.0) | 277 | 1.0 | (0.8–1.2) | 198 | 0.8 | (0.6–0.9) | |
| Any heart disease [¶] | 3,218 | 11.3 | (10.9–11.8) | 98 | 18.3 | (14.7–22.6) | 61 | 19.5 | (14.3–25.9) | 35 | 16.7 | (11.9–22.9) | |
| Hypertension | 8,647 | 29.0 | (28.4–29.6) | 194 | 34.2 | (29.7–39.0) | 124 | 34.7 | (28.7-41.2) | 68 | 32.2 | (25.3–40.0) | |
| Stroke | 768 | 2.4 | (2.2–2.7) | 72 | 14.3 | (11.1–18.2) | 54 | 18.3 | (13.4–24.4) | 17 | 8.8 | (5.6–13.6) | |
| Diabetes mellitus | 2,709 | 8.7 | (8.2–9.1) | 58 | 10.4 | (7.7–14.0) | 38 | 10.5 | (7.3–14.9) | 19 | 9.2 | (5.3–15.4) | |
| Prediabetes | 1,071 | 4.3 | (3.9–4.6) | 35 | 7.1 | (4.7–10.4) | _ | ** | ** | _ | _ | _ | |
| Normal/underweight | 9,514 | 38.1 | (37.3–38.9) | 144 | 32.8 | (27.5–38.6) | 83 | 34.7 | (27.0-43.3) | 59 | 32.5 | (25.5-40.4) | |
| Overweight | 8,938 | 34.5 | (33.7–35.2) | 153 | 33.1 | (28.4–38.2) | 94 | 37.1 | (30.0-44.8) | 57 | 27.2 | (20.8-34.6) | |
| Obese | 7,247 | 27.5 | (26.7–28.2) | 163 | 34.1 | (28.9–39.8) | 89 | 28.2 | (21.8–35.5) | 74 | 40.3 | (32.0-48.2) | |
| Emphysema | 500 | 1.7 | (1.5–2.0) | 30 | 5.5 | (3.5-8.3) | 20 | 6.2 | (3.7–10.0) | _ | _ | — | |
| Chronic bronchitis | 1,171 | 4.1 | (3.8–4.5) | 42 | 7.5 | (5.2–10.6) | 27 | 8.5 | (5.2–13.3) | _ | _ | — | |
| Asthma | 3,243 | 12.6 | (12.0–13.2) | 104 | 19.2 | (15.2–24.0) | 58 | 17.0 | (12.3–23.0) | 43 | 19.9 | (14.1–27.4) | |
| Current asthma | 2,142 | 65.0 | (62.8–67.0) | 74 | 59.8 | (47.2–71.1) | 45 | 67.4 | (48.4-82.0) | 26 | 55.1 | (38.8–70.4) | |
| Asthma attack in past 12 mos | 1,106 | 32.6 | (30.7-34.6) | 49 | 36.6 | (25.9–48.7) | 32 | 51.9 | (34.8–68.6) | 15 | 28.7 | (18.8–41.3) | |
| Hay fever | 1,975 | 7.6 | (7.1-8.0) | 47 | 7.5 | (5.4–10.4) | 29 | 8.1 | (5.0-12.8) | 18 | 7.1 | (4.1–11.9) | |
| Sinusitis | 3,418 | 12.6 | (12.1–13.2) | 86 | 15.6 | (12.2–19.7) | 48 | 14.7 | (10.3–20.4) | 37 | 16.3 | (11.5–22.6) | |
| Dermatitis | 2,556 | 10.0 | (9.4–10.5) | 83 | 17.5 | (13.5–22.3) | 46 | 15.8 | (11.3–21.7) | 36 | 19.5 | (13.7–27.0) | |
| Arthritis | 6,250 | 21.4 | (20.8-22.0) | 180 | 30.9 | (27.3–34.8) | 114 | 31.3 | (26.1-37.0) | 64 | 29.0 | (23.1–35.5) | |
| Pain or stiffness in a joint | 8,832 | 31.9 | (31.2-32.7) | 257 | 47.5 | (42.4–52.6) | 158 | 49.1 | (41.7–56.5) | 96 | 44.9 | (37.3–52.7) | |
| Neck pain | 4,240 | 15.2 | (14.6–15.8) | 143 | 25.7 | (21.3-30.8) | 89 | 28.5 | (22.3–35.6) | 51 | 22.7 | (16.8–29.9) | |
| Low back pain | 7,736 | 28.2 | (27.4–29.0) | 219 | 40.1 | (35.2–45.3) | 129 | 40.9 | (33.8–48.5) | 87 | 39.9 | (32.1–48.1) | |
| Sciatica | 2,883 | 34.3 | (33.0-35.7) | 124 | 58.3 | (49.2–66.9) | 73 | 60.8 | (48.9–71.5) | 49 | 54.1 | (41.9–65.9) | |
| Facial ache or pain in the jaw | 1,256 | 4.8 | (4.4–5.2) | 73 | 14.2 | (10.7–18.6) | 43 | 13.4 | (9.1–19.4) | 28 | 14.2 | (9.1–21.4) | |
| Severe headache or migraine | 4,277 | 16.2 | (15.7–16.8) | 174 | 34.7 | (30.1–39.5) | 104 | 35.5 | (28.5-43.1) | 69 | 33.7 | (26.8-41.4) | |
| Cancer | 2,269 | 8.1 | (7.7-8.5) | 62 | 11.3 | (8.6–14.9) | 41 | 11.2 | (7.9–15.8) | 20 | 11.5 | (7.0–18.5) | |
| Ulcer | 1,798 | 6.2 | (5.8–6.6) | 69 | 12.4 | (9.2–16.5) | 38 | 11.5 | (8.0–16.2) | 28 | 15.2 | (9.8–22.9) | |
| Ulcer in the past 12 mos | 501 | 28.9 | (25.8–32.1) | 31 | 47.1 | (32.7–61.9) | 19 | 45.3 | (28.4–63.4) | 10 | 45.6 | (27.9–64.5) | |
| Liver condition | 404 | 1.3 | (1.1–1.5) | 18 | 3.0 | (1.7–5.0) | | _ | _ | _ | _ | | |

TABLE. Percentage* of adults with selected nonpsychiatric conditions,[†] by epilepsy status — National Health Interview Survey, United States, 2010

Abbreviation: CI = confidence interval.

* Tabulated percentages were age-adjusted to 2000 U.S. Population Census estimates. The age groups used for adjustment were 18–44, 45–64, 65–74, and ≥75 years.

⁺ Based on reporting to a doctor or other health professional or being told by a doctor or other health professional. For different conditions, the time period asked differed (e.g., condition or symptoms in past 12 months, 3 months, or 30 days). Additional information available at http://www.cdc.gov/nchs/nhis_questionnaires.htm.

[§] The number of respondents is unweighted; the percentage estimates are weighted.

[¶] Includes coronary heart disease, angina pectoris, heart attack, or any other heart condition or disease.

** Relative standard error exceeded 30%.

than adults without epilepsy (4.3%). Adults with any epilepsy (34.1%) and inactive epilepsy (40.3%) were more likely to be obese than adults without epilepsy (27.5%).

Considering respiratory disorders, more adults with any epilepsy (5.5%) and active epilepsy (6.2%) had emphysema than those without the disorder (1.7%). More adults with any epilepsy (7.5%) and active epilepsy (8.5%) had chronic bronchitis in the past year than adults without epilepsy (4.1%). More adults with any epilepsy (19.2%) and inactive epilepsy (19.9%) had asthma than those without epilepsy (12.6%). However, adults with active epilepsy were more likely to have had an asthma attack in the past year (51.9%) than adults without epilepsy (32.6%).

Some disorders that can be caused or mediated by inflammation also were more common in adults with epilepsy. For example, significantly more adults across all epilepsy groups than adults without epilepsy had a history of dermatitis, arthritis, recent joint pain, and other types of pain including, neck, facial, and low back pain. Across all groups, more than twice as many adults with epilepsy than adults without epilepsy had experienced recent, severe headache or migraine.

Cancer was more common in adults with any epilepsy (11.3%) than adults without epilepsy (8.1%). Adults with any epilepsy were more likely to have had peptic ulcer disease and to have had ulcer symptoms in the past year than adults without epilepsy. More adults with any epilepsy had a liver condition than those without epilepsy. In addition, adults with epilepsy, especially active epilepsy, were more likely to report four or more medical comorbidities and less likely to report no other comorbidities than adults without epilepsy (Figure).

Reported by

Norbert T. Kadima, MStat, SciMetrika, Research Triangle Park, North Carolina. Rosemarie Kobau, MPH, MAPP, Matthew M. Zack, MD, Sandra Helmers, MD, Div of Population Health, National Center for Chronic Disease Prevention and Health Promotion, CDC. **Corresponding contributor:** Rosemarie Kobau, rkobau@cdc.gov, 770-488-6087.




FIGURE. Percentage* of adults with selected nonpsychiatric conditions,[†] by number of conditions and epilepsy status — National Health Interview Survey, United States, 2010

* Unadjusted estimates.

[†] Includes self-reported heart disease (coronary heart disease, angina pectoris, myocardial infarction or any other heart disease); high blood pressure; stroke; diabetes mellitus; prediabetes; emphysema; chronic bronchitis; asthma; hay fever; sinusitis; dermatitis/eczema; arthritis; joint pain, aching, or stiffness; neck pain; low back pain; facial or jaw pain; severe headaches or migraine; cancer; ulcer; liver condition; and overweight/obesity (body mass index ≥25).

[§] Because of different methodologies, estimates of comorbidities among adults with no history of epilepsy differ from those in a previously published report (Ward BW, Schiller JS. Prevalence of multiple chronic conditions among US adults: estimates from the National Health Interview Survey, 2010. Prev Chronic Dis. 2013;10:E65).

Editorial Note

In this study, many U.S. adults with epilepsy (especially those with active epilepsy) reported cardiovascular, respiratory, and other disorders and various types of pain, consistent with other U.S. and international reports (2,4,6). These disorders might result from shared disease mechanisms (e.g., migraine or stroke), social disadvantages associated with chronic disease (e.g., risk-factor clustering), treatment side effects (e.g., weight gain), or shared genetic, environmental, or other factors (2,5,8). Adults with epilepsy also report higher rates of smoking and physical inactivity (3), which increase risk for heart disease and respiratory disorders.

This study aligns with the U.S. Department of Health and Human Services Initiative on Multiple Chronic Conditions by identifying the burden of co-occurring conditions in adults with epilepsy to foster more encompassing approaches to address this burden (9). Although controlling seizures is a priority for epilepsy care, preventing, limiting, and reversing associated comorbidity remains critical to improving health and quality of life (2, 10). The added challenges of managing multiple comorbidities among adults with epilepsy can further threaten their well-being and ability to function optimally (5). Thus, improved awareness and understanding among neurologists and primary-care providers regarding the common medical comorbidities reported with epilepsy along with better screening, diagnosis, and treatment of comorbidity in persons with epilepsy are necessary. A previous study found that most adults with epilepsy visited a general doctor in the preceding year, but only about one third saw a neurologist or epilepsy specialist (1). The extent to which evidence-based practice guidelines are used remains unclear (2), and healthcare providers might focus only on one condition, ignoring care coordination (9). Managing comorbidity requires that primary and specialty-care providers work together to help patients with epilepsy manage both their epilepsy and other disorders, using appropriate clinical guidelines (2).

What is already known on this topic?

Persons with epilepsy might be at increased risk for some mental and physical disorders.

What is added by this report?

This study, based on the 2010 National Health Interview Survey, found that adults with epilepsy reported co-occurring cardio-vascular, respiratory, some inflammatory, and other disorders more frequently than respondents without epilepsy.

What are the implications for public health practice?

Epidemiologic studies to show how epilepsy is related to these comorbid conditions could help identify preventable risk factors. Greater collaboration among public health agencies, health-care providers, the Epilepsy Foundation, and other partners might ensure that adults with epilepsy have access to chronic disease self-management programs and to general disease prevention and health promotion information and services.

The findings in this report are subject to at least eight limitations. First, because the estimates rely on self-reported data, they might be subject to reporting bias; however, comparable findings in other population surveys suggest bias is minimal (3). Second, the reported cases of epilepsy are not classified by seizure type, severity, or etiology. Third, certain acute seizures or nonepileptic seizures might have been misclassified as epilepsy, thus overestimating prevalence. However, significant skewing of results is unlikely because of the low incidence of nonepileptic seizures in the general population (1,3). Fourth, epilepsy prevalence might be underestimated because of underreporting associated with repercussions from disclosing epilepsy (1,3)and the exclusion of institutionalized adults from NHIS. Fifth, because the onset of epilepsy relative to that of the other cooccurring disorders is unknown, inferring causation or overlap between these disorders is difficult. Sixth, small sample sizes limited comparisons. Seventh, the low response rate could have understated or overstated these associations. Finally, because of different study methodologies, estimates of comorbidities differ from those in a previous report.**

Ensuring that adults with epilepsy are screened for common risk factors might help prevent onset of co-occurring disorders that can worsen quality of life over time. Preventing stroke, a common risk factor for epilepsy in adults, also might minimize epilepsy incidence in those at higher risk (e.g., adults who have experienced prior head trauma) (2). Future studies can look at mechanisms that relate epilepsy to these comorbid conditions. Evidence-based programs that can help adults with epilepsy learn effective self-management skills (e.g., medication adherence and emotional management) are available.^{††} Greater collaboration among public health agencies, health-care providers, local Epilepsy Foundation affiliates, and other community epilepsy groups might ensure that adults with epilepsy have access to chronic disease self-management programs and to health promotion resources (e.g., smoking cessation programs and interventions to reduce obesity).

^{††} Information regarding epilepsy self-management programs is available at http://www.cdc.gov/epilepsy.

References

- 1. CDC. Epilepsy in adults and access to care—United States, 2010. MMWR 2012;61;909–13.
- Institute of Medicine. Epilepsy across the spectrum: promoting health and understanding. Washington, DC: The National Academy Press; 2012. Available at http://www.iom.edu/epilepsy.
- 3. CDC. Epilepsy surveillance among adults—19 states, Behavioral Risk Factor Surveillance System, 2005. MMWR 2008;57(No. SS-6).
- 4. Sander JW. Comorbidity and premature mortality in epilepsy. Lancet 2013; [Epub ahead of print].
- Institute of Medicine. Living well with chronic illness: a call for public health action. Washington, DC: The National Academies Press; 2012. Available at http://www.nap.edu/openbook.php?record_id=13272.
- 6. Ottman R, Lipton RB, Ettinger AB, et al. Comorbidities of epilepsy: results from the Epilepsy Comorbidities and Health (EPIC) survey. Epilepsia 2011;52:308–15.
- 7. Tellez-Zenteno JF, Patten SB, Jetté N, Williams J, Wiebe S. Psychiatric comorbidity in epilepsy: a population-based analysis. Epilepsia 2007;48:2336–44.
- Schuit AJ, van Loon AJ, Tijhuis M, Ocké MC. Clustering of lifestyle risk factors in a general adult population. Prev Med 2002;35:219–24.
- 9. Parekh AK, Goodman RA, Gordon C, Koh HK, HHS Interagency Workgroup on Multiple Chronic Conditions. Managing multiple chronic conditions: a strategic framework for improving health outcomes and quality of life. Pub Health Reports 2011;126:460–71.
- National Institute of Neurological Disorders and Stroke. 2007 epilepsy research benchmarks. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health; 2013. Available at http:// www.ninds.nih.gov/research/epilepsyweb/2007_benchmarks.htm.

^{**} Ward BW, Schiller JS. Prevalence of multiple chronic conditions among US adults: estimates from the National Health Interview Survey, 2010. Prev Chronic Dis 2013;10:E65.